This was a crossover study comparing a mucin-based artificial saliva (Saliva Orthana™) and pilocarpine hydrochloride (Salagen™) in the management of xerostomia in patients with advanced cancer. The pilocarpine was found to be more effective than the artificial saliva in terms of mean change in visual analogue scale scores for xerostomia (P = 0.003). Furthermore, more patients reported that it had helped their xerostomia, and more patients wanted to continue with it after the study. However, the pilocarpine was found to be associated with more side-effects than the artificial saliva (P < 0.001). These side-effects were usually reported as being mild. Of the patients who used both treatments, 50% preferred the artificial saliva, and 50% preferred the pilocarpine. The commonest reason for preferring the artificial saliva was the fact that it was a spray, rather than a tablet.
Sreebny LM. Xerostomia: diagnosis, management and clinical complications. In: Edgar WM, O'Mullane DM eds. Saliva and oral health. London: British Dental Association, 1996; 43–66.
2.
Sreebny LM, Valdini A. Xerostomia. Part 1: relationship to other oral symptoms and salivary gland hypofunction. Oral Surg Oral Med Oral Pathol1988; 66: 451–458.
3.
Pankhurst CL, Smith EC, Rogers JO, Dunne SM, Jackson SHD, Procter G. Diagnosis and management of the dry mouth: part 1. Dent Update1996; 23: 56–62.
4.
Ventafridda V, De Conno F, Ripamonti C, Gamba A, Tamburini M. Quality-of-life assessment during a palliative care programme. Ann Oncol1990; 1: 415–420.
5.
Jobbins J, Bagg J, Finlay IG, Addy M, Newcombe RG. Oral and dental disease in terminally ill cancer patients. Br Med J1992; 304: 1612.
6.
Addington-Hall J, McCarthy M. Dying from cancer: results of a national population-based investigation. Palliat Med1995; 9: 295–305.
7.
Twycross RG, Lack SA. The mouth. In: Twycross RG, Lack SA eds. Control of alimentary symptoms in far advanced cancer. Edinburgh: Churchill Livingstone, 1986: 12–39.
8.
Davies AN. The management of xerostomia: a review. Eur J Cancer Care1997; 6: 209–214.
9.
Sweeney MP, Bagg J, Baxter WP, Aitchison TC. Clinical trial of a mucin-containing oral spray for treatment of xerostomia in hospice patients. Palliat Med1997; 11: 225–232.
10.
Addington-Hall JM, MacDonald LD, Anderson HR et al. Randomised controlled trial of effects of coordinating care for terminally ill cancer patients. Br Med J1992; 305: 1317–1322.
11.
McWhinney IR, Bass MJ, Donner A. Evaluation of a palliative care service: problems and pitfalls. Br Med J1994; 309: 1340–1342.
12.
Spielman A, Ben-Aryeh H, Gutman D, Szargel R, Deutsch E. Xerostomia–diagnosis and treatment. Oral Surg Oral Med Oral Pathol1981; 51: 144–147.
13.
Aagaard A, Godiksen S, Teglers PT, Schiodt M, Glenert U. Comparison between new saliva stimulants in patients with dry mouth: a placebo-controlled double-blind crossover study. J Oral Pathol Med1992; 21: 376–380.
14.
Blom M, Dawidson I, Angmar-Mansson B. The effect of acupuncture on salivary flow rates in patients with xerostomia. Oral Surg Oral Med Oral Pathol1992; 73: 293–298.
15.
's-Gravenmade EJ, Roukema PA, Panders AK. The effect of mucin-containing artificial saliva on severe xerostomia. Int J Oral Surg1974; 3: 435–439.
16.
Vissink A, 's-Gravenmade EJ, Panders AK et al. A clinical comparison between commercially available mucin- and CMC-containing saliva substitutes. Int J Oral Surg1983; 12: 232–238.
17.
Visch LL, 's-Gravenmade EJ, Schaub RM, Van Putten WL, Vissink A. A double-blind crossover trial of CMC- and mucin-containing saliva substitutes. Int J Oral Maxillofac Surg1986; 15: 395–400.
18.
's-Gravenmade EJ, Panders AK. Clinical applications of saliva substitutes. Front Oral Physiol1981; 3: 154–161.
19.
Olsson H, Axell T. Objective and subjective efficacy of saliva substitutes containing mucin and carboxymethylcellulose. Scand J Dent Res1991; 99: 316–319.
20.
Davies AN, Singer J. A comparison of artificial saliva and pilocarpine in radiation-induced xerostomia. J Laryngol Otol1994; 108: 663–665.
21.
Ferguson MM. Pilocarpine and other cholinergic drugs in the management of salivary gland dysfunction. Oral Surg Oral Med Oral Pathol1993; 75: 186–191.
22.
Fox PC, van der Ven PF, Baum BJ, Mandel ID. Pilocarpine for the treatment of xerostomia associated with salivary gland dysfunction. Oral Surg Oral Med Oral Pathol1986; 61: 243–248.
23.
Greenspan D, Daniels TE. Effectiveness of pilocarpine in postradiation xerostomia. Cancer1987; 59: 1123–1125.
24.
Fox PC, Atkinson JC, Macynski AA et al. Pilocarpine treatment of salivary gland hypofunction and dry mouth (xerostomia). Arch Intern Med1991; 151: 1149–1152.
25.
Schuller DE, Stevens P, Clausen KP, Olsen J, Gahbauer R, Martin M. Treatment of radiation side effects with oral pilocarpine. J Surg Oncol1989; 42: 272–276.
26.
Le Veque FG, Montgomery M, Potter D et al. A multicenter, randomized, double-blind, placebo-controlled, dose–titration study of oral pilocarpine for treatment of radiation-induced xerostomia in head and neck cancer patients. J Clin Oncol1993; 11: 1124–1131.
27.
Johnson JT, Ferretti GA, Nethery WJ et al. Oral pilocarpine for post-irradiation xerostomia in patients with head and neck cancer. N Engl J Med1993; 329: 390–395.
28.
Rieke JW, Hafermann MD, Johnson JT et al. Oral pilocarpine for radiation-induced xerostomia: integrated efficacy and safety results from two prospective randomized clinical trials. Int J Radiat Oncol Biol Phys1995; 31: 661–669.
29.
Chambers MS, Toth BB, King GE, Keene HJ, Muscoplat CC, Payne R. A single-center, single-blind, pilot study to assess Salagen tablets as treatment for xerostomia associated with the use of analgesics for chronic cancer pain [Abstract]. Proc ASCO1996; 15: 1787.
30.
Salah RS, Cameron OG. Pilocarpine for anticholinergic adverse effects associated with desipramine treatment. Am J Psychiatry1996; 153: 579.
31.
Lockhart PB, Fox PC, Gentry AC, Acharya R, Norton HJ. Pilot study of controlled-release pilocarpine in normal subjects. Oral Surg Oral Med Oral Pathol Oral Radiol Endod1996; 82: 517–524.
32.
Bjornstrom M, Axell T, Birkhed D. Comparison between saliva stimulants and saliva substitutes in patients with symptoms related to dry mouth. A multi-centre study. Swed Dent J1990; 14: 153–161.
